Association of Cognitive Deficit with Glutamate and Insulin Signaling in a Rat Model of Parkinson’s Disease
Abstract
:1. Introduction
2. Materials and Methods
2.1. Animals
2.2. Ethics
2.3. Experimental Rat Model of Parkinson’s Disease
2.4. Cognitive Testing
2.5. MWM
2.6. PA
2.7. Tissue Preparation
2.8. Immunofluorescence
2.9. Insulin Concentration Measurement
2.10. Western Blot Analysis
2.11. Statistics
3. Results
3.1. 6-OHDA Administration Induced Learning and Memory Deficit
3.2. 6-OHDA Administration Induced Dopaminergic Neurodegeneration (Reduced TH Levels) in the Cortex, HPC, HPT and S, while Dopaminergic Nuclei in the Substantia Nigra Were Found Preserved
3.3. A Total of 3 Months after 6-OHDA Administration, No Changes Were Observed in the Level of Proteins Involved in Insulin Signaling
3.4. 6-OHDA Induced Decrement of Phosphorylated AMPAR Levels in the HPC and S
3.5. 6-OHDA Induces Regionally Specific Correlations
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Dorsey, E.R.; Sherer, T.; Okun, M.S.; Bloemd, B.R. The emerging evidence of the Parkinson pandemic. J. Park. Dis. 2018, 8, S3–S8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marras, C.; Chaudhuri, K.R. Nonmotor features of Parkinson’s disease subtypes. Mov. Disord. 2016, 31, 1095–1102. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aarsland, D.; Bronnick, K.; Williams-Gray, C.; Weintraub, D.; Marder, K.; Kulisevsky, J.; Burn, D.; Barone, P.; Pagonabarraga, J.; Allcock, L.; et al. Mild cognitive impairment in Parkinson disease: A multicenter pooled analysis. Neurology 2010, 75, 1062–1069. [Google Scholar] [CrossRef] [PubMed]
- Litvan, I.; Aarsland, D.; Adler, C.H.; Goldman, J.G.; Kulisevsky, J.; Mollenhauer, B.; Rodriguez-Oroz, M.C.; Tröster, A.I.; Weintraub, D. MDS task force on mild cognitive impairment in Parkinson’s disease: Critical review of PD-MCI. Mov. Disord. 2011, 26, 1814–1824. [Google Scholar] [CrossRef] [Green Version]
- Damier, P.; Hirsch, E.C.; Agid, Y.; Graybiel, A.M. The substantia nigra of the human brain: II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain 1999, 122, 1437–1448. [Google Scholar] [CrossRef] [PubMed]
- Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.Y.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. α-synuclein in Lewy bodies. Nature 1997, 388, 839–840. [Google Scholar] [CrossRef] [PubMed]
- Caligiore, D.; Giocondo, F.; Silvetti, M. The Neurodegenerative Elderly Syndrome (NES) hypothesis: Alzheimer and Parkinson are two faces of the same disease. IBRO Neurosci. Rep. 2022, 13, 330–343. [Google Scholar] [CrossRef] [PubMed]
- Fang, C.; Lv, L.; Mao, S.; Dong, H.; Liu, B. Cognition Deficits in Parkinson’s Disease: Mechanisms and Treatment. Park. Dis. 2020, 2020, 2076942. [Google Scholar] [CrossRef] [Green Version]
- Hölscher, C. Brain insulin resistance: Role in neurodegenerative disease and potential for targeting. Expert Opin. Investig. Drugs 2020, 29, 333–348. [Google Scholar] [CrossRef]
- De Pablo-Fernández, E.; Breen, D.P.; Bouloux, P.M.; Barker, R.A.; Foltynie, T.; Warner, T.T. Neuroendocrine abnormalities in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 2017, 88, 176–185. [Google Scholar] [CrossRef] [Green Version]
- Choi, J.-Y.; Jang, E.-H.; Park, C.-S.; Kang, J.-H. Enhanced susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity. Free Radic. Biol. Med. 2005, 38, 806–816. [Google Scholar] [CrossRef]
- Morris, J.K.; Zhang, H.; Gupte, A.A.; Bomhoff, G.L.; Stanford, J.A.; Geiger, P.C. Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson’s disease. Brain Res. 2008, 1240, 185–195. [Google Scholar] [CrossRef] [Green Version]
- Wang, L.; Zhai, Y.-Q.; Xu, L.-L.; Qiao, C.; Sun, X.-L.; Ding, J.-H.; Lu, M.; Hu, G. Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice. Exp. Neurol. 2014, 251, 22–29. [Google Scholar] [CrossRef]
- Bassil, F.; Delamarre, A.; Canron, M.H.; Dutheil, N.; Vital, A.; Négrier-Leibreich, M.L.; Bezard, E.; Fernagut, P.O.; Meissner, W.G. Impaired brain insulin signalling in Parkinson’s disease. Neuropathol. Appl. Neurobiol. 2022, 48, e12760. [Google Scholar] [CrossRef] [PubMed]
- Athauda, D.; Foltynie, T. Insulin resistance and Parkinson’s disease: A new target for disease modification? Prog. Neurobiol. 2016, 145–146, 98–120. [Google Scholar] [CrossRef]
- Wang, J.; Wang, F.; Mai, D.; Qu, S. Molecular Mechanisms of Glutamate Toxicity in Parkinson’s Disease. Front. Neurosci. 2020, 14, 585584. [Google Scholar] [CrossRef]
- Meredith, G.E.; Totterdell, S.; Beales, M.; Meshul, C.K. Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson’s disease. Exp. Neurol. 2009, 219, 334–340. [Google Scholar] [CrossRef] [Green Version]
- Sonsalla, P.K.; Albers, D.S.; Zeevalk, G.D. Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism. Amino Acids 1998, 14, 69–74. [Google Scholar] [CrossRef] [PubMed]
- Iovino, L.; Tremblay, M.E.; Civiero, L. Glutamate-induced excitotoxicity in Parkinson’s disease: The role of glial cells. J. Pharmacol. Sci. 2020, 144, 151–164. [Google Scholar] [CrossRef] [PubMed]
- Lindgren, H.S.; Lelos, M.J.; Dunnett, S.B. Do alpha-synuclein vector injections provide a better model of Parkinson’s disease than the classic 6-hydroxydopamine model? Exp. Neurol. 2012, 237, 36–42. [Google Scholar] [CrossRef]
- Deumens, R.; Blokland, A.; Prickaerts, J. Modeling Parkinson’s disease in rats: An evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 2002, 175, 303–317. [Google Scholar] [CrossRef] [Green Version]
- Hritcu, L.; Ciobica, A.; Artenie, V. Effects of right-unilateral 6-hydroxydopamine infusion-induced memory impairment and oxidative stress: Relevance for Parkinson’s disease. Open Life Sci. 2008, 3, 250–257. [Google Scholar] [CrossRef]
- Kuruvilla, K.P.; Nandhu, M.S.; Paul, J.; Paulose, C.S. Oxidative stress mediated neuronal damage in the corpus striatum of 6-hydroxydopamine lesioned Parkinson’s rats: Neuroprotection by Serotonin, GABA and Bone Marrow Cells Supplementation. J. Neurol. Sci. 2013, 331, 31–37. [Google Scholar] [CrossRef] [PubMed]
- More, S.; Kumar, H.; Cho, D.-Y.; Yun, Y.-S.; Choi, D.-K. Toxin-Induced Experimental Models of Learning and Memory Impairment. Int. J. Mol. Sci. 2016, 17, 1447. [Google Scholar] [CrossRef] [Green Version]
- Tadaiesky, M.T.; Dombrowski, P.A.; Figueiredo, C.P.; Cargnin-Ferreira, E.; Da Cunha, C.; Takahashi, R.N. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson’s disease. Neuroscience 2008, 156, 830–840. [Google Scholar] [CrossRef]
- Sauer, H.; Oertel, W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994, 59, 401–415. [Google Scholar] [CrossRef] [PubMed]
- Blandini, F.; Levandis, G.; Bazzini, E.; Nappi, G.; Armentero, M.T. Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: New clues from an old model. Eur. J. Neurosci. 2007, 25, 397–405. [Google Scholar] [CrossRef]
- Lee, C.S.; Sauer, H.; Björklund, A. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat. Neuroscience 1996, 72, 641–653. [Google Scholar] [CrossRef] [PubMed]
- Pallav Sengupta The Laboratory Rat: Relating its Age with Human’s. Int. J. Prev. Med. 2013, 4, 624–630.
- Roedter, A.; Winkler, C.; Samii, M.; Walter, G.F.; Brandis, A.; Nikkhah, G. Comparison of unilateral and bilateral intrastriatal 6-hydroxydopamine-induced axon terminal lesions: Evidence for interhemispheric functional coupling of the two nigrostriatal pathways. J. Comp. Neurol. 2001, 432, 217–229. [Google Scholar] [CrossRef]
- Homolak, J.; Joja, M.; Grabaric, G.; Schiatti, E.; Virag, D.; Babic Perhoc, A.; Knezovic, A.; Osmanovic Barilar, J.; Salkovic-Petrisic, M. The absence of gastrointestinal redox dyshomeostasis in the brain-first rat model of Parkinson’s disease induced by bilateral intrastriatal 6-hydroxydopamine. bioRxiv 2022, 2022, 504759. [Google Scholar] [CrossRef]
- Vorhees, C.V.; Williams, M.T. Morris water maze: Procedures for assessing spatial and related forms of learning and memory. Nat. Protoc. 2006, 1, 848–858. [Google Scholar] [CrossRef] [Green Version]
- Knezovic, A.; Osmanovic-Barilar, J.; Curlin, M.; Hof, P.R.; Simic, G.; Riederer, P.; Salkovic-Petrisic, M. Staging of cognitive deficits and neuropathological and ultrastructural changes in streptozotocin-induced rat model of Alzheimer’s disease. J. Neural Transm. 2015, 122, 577–592. [Google Scholar] [CrossRef] [Green Version]
- Barilar, J.O.; Knezovic, A.; Homolak, J.; Perhoc, A.B.; Salkovic-Petrisic, M. Divergent Effect of Central Incretin Receptors Inhibition in a Rat Model of Sporadic Alzheimer’s Disease. Int. J. Mol. Sci. 2022, 23, 548. [Google Scholar] [CrossRef]
- Lowry, O.H.; Rosebrough, N.J.; Farr, A.L.; Randall, R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265–275. [Google Scholar] [CrossRef] [PubMed]
- Knezovic, A.; Budisa, S.; Babic Perhoc, A.; Homolak, J.; Osmanovic Barilar, J. From determining brain insulin resistance in a sporadic Alzheimer’s disease model to exploring the region-dependent effect of intranasal insulin. Mol. Neurobiol. 2023, 60. [Google Scholar] [CrossRef]
- Faraji, J.; Metz, G.A. Sequential bilateral striatal lesions have additive effects on single skilled limb use in rats. Behav. Brain Res. 2007, 177, 195–204. [Google Scholar] [CrossRef] [PubMed]
- Bonito-Oliva, A.; Pignatelli, M.; Spigolon, G.; Yoshitake, T.; Seiler, S.; Longo, F.; Piccinin, S.; Kehr, J.; Mercuri, N.B.; Nisticò, R.; et al. Cognitive impairment and dentate gyrus synaptic dysfunction in experimental Parkinsonism. Biol. Psychiatry 2014, 75, 701–710. [Google Scholar] [CrossRef]
- da Silva, T.P.; Poli, A.; Hara, D.B.; Takahashi, R.N. Time course study of microglial and behavioral alterations induced by 6-hydroxydopamine in rats. Neurosci. Lett. 2016, 622, 83–87. [Google Scholar] [CrossRef]
- Asl, M.M.; Vahabie, A.H.; Valizadeh, A. Review paper: Dopaminergic modulation of synaptic plasticity, its role in neuropsychiatric disorders, and its computational modeling. Basic Clin. Neurosci. 2019, 10, 1–12. [Google Scholar] [CrossRef]
- Campos, F.L.; Carvalho, M.M.; Cristovão, A.C.; Je, G.; Baltazar, G.; Salgado, A.J.; Kim, Y.-S.; Sousa, N. Rodent models of Parkinson’s disease: Beyond the motor symptomatology. Front. Behav. Neurosci. 2013, 7, 175. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hsueh, S.C.; Chen, K.Y.; Lai, J.H.; Wu, C.C.; Yu, Y.W.; Luo, Y.; Hsieh, T.H.; Chiang, Y.H. Voluntary physical exercise improves subsequent motor and cognitive impairments in a rat model of parkinson’s disease. Int. J. Mol. Sci. 2018, 19, 508. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Su, R.J.; Zhen, J.L.; Wang, W.; Zhang, J.L.; Zheng, Y.; Wang, X.M. Time-course behavioral features are correlated with Parkinson’s disease-associated pathology in a 6-hydroxydopamine hemiparkinsonian rat model. Mol. Med. Rep. 2018, 17, 3356–3363. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tabrez, S.; Jabir, R.N.; Shakil, S.; Greig, H.N.; Alam, Q.; Abuzenadah, M.A.; Damanhouri, A.G.; Kamal, A.M. A Synopsis on the Role of Tyrosine Hydroxylase in Parkinson’s Disease. CNS Neurol. Disord.-Drug Targets 2012, 11, 395–409. [Google Scholar] [CrossRef]
- Daubner, S.C.; Le, T.; Wang, S. Tyrosine hydroxylase and regulation of dopamine synthesis. Arch. Biochem. Biophys. 2011, 508, 1–12. [Google Scholar] [CrossRef] [Green Version]
- Lisman, J.E.; Otmakhova, N.A. Storage, recall, and novelty detection of sequences by the hippocampus: Elaborating on the SOCRATIC model to account for normal and aberrant effects of dopamine. Hippocampus 2001, 11, 551–568. [Google Scholar] [CrossRef]
- Folgueira, C.; Beiroa, D.; Porteiro, B.; Duquenne, M.; Puighermanal, E.; Fondevila, M.F.; Barja-Fernández, S.; Gallego, R.; Hernández-Bautista, R.; Castelao, C.; et al. Hypothalamic dopamine signalling regulates brown fat thermogenesis. Nat. Metab. 2019, 1, 811–829. [Google Scholar] [CrossRef]
- Chen, A.P.F.; Chen, L.; Kim, T.A.; Xiong, Q. Integrating the roles of midbrain dopamine circuits in behavior and neuropsychiatric disease. Biomedicines 2021, 9, 647. [Google Scholar] [CrossRef]
- Tsetsenis, T.; Badyna, J.K.; Wilson, J.A.; Zhang, X.; Krizman, E.N.; Subramaniyan, M.; Yang, K.; Thomas, S.A.; Dani, J.A. Midbrain dopaminergic innervation of the hippocampus is sufficient to modulate formation of aversive memories. Proc. Natl. Acad. Sci. USA 2021, 118, e2111069118. [Google Scholar] [CrossRef]
- Wang, Z.Y.; Lian, H.; Cai, Q.Q.; Song, H.Y.; Zhang, X.L.; Zhou, L.; Zhang, Y.M.; Zheng, L.F.; Zhu, J.X. No direct projection is observed from the substantia nigra to the dorsal vagus complex in the rat. J. Park. Dis. 2014, 4, 375–383. [Google Scholar] [CrossRef] [Green Version]
- Yonemochi, N.; Ardianto, C.; Yang, L.; Yamamoto, S.; Ueda, D.; Kamei, J.; Waddington, J.L.; Ikeda, H. Dopaminergic mechanisms in the lateral hypothalamus regulate feeding behavior in association with neuropeptides. Biochem. Biophys. Res. Commun. 2019, 519, 547–552. [Google Scholar] [CrossRef] [PubMed]
- Goodroe, S.C.; Starnes, J.; Brown, T.I. The Complex Nature of Hippocampal-Striatal Interactions in Spatial Navigation. Front. Hum. Neurosci. 2018, 12, 250. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Suzuki, K.; Okada, K.; Wakuda, T.; Shinmura, C.; Kameno, Y.; Iwata, K.; Takahashi, T.; Suda, S.; Matsuzaki, H.; Iwata, Y.; et al. Destruction of dopaminergic neurons in the midbrain by 6-hydroxydopamine decreases hippocampal cell proliferation in rats: Reversal by fluoxetine. PLoS ONE 2010, 2, e9260. [Google Scholar] [CrossRef]
- Masini, D.; Plewnia, C.; Bertho, M.; Scalbert, N.; Caggiano, V.; Fisone, G. A guide to the generation of a 6-hydroxydopamine mouse model of Parkinson’s disease for the study of non-motor symptoms. Biomedicines 2021, 9, 598. [Google Scholar] [CrossRef]
- Barilar, J.O.; Knezovic, A.; Perhoc, A.B.; Homolak, J.; Riederer, P.; Salkovic-Petrisic, M. Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer’s and Parkinson’s disease. J. Neural Transm. 2020, 127, 231–250. [Google Scholar] [CrossRef] [Green Version]
- Concetti, C.; Bracey, E.F.; Peleg-Raibstein, D.; Burdakov, D. Control of fear extinction by hypothalamic melanin-concentrating hormone–expressing neurons. Proc. Natl. Acad. Sci. USA 2020, 117, 22514–22521. [Google Scholar] [CrossRef]
- De Castro Medeiros, D.; Aguiar, C.L.; Moraes, M.F.D.; Fisone, G. Sleep disorders in rodent models of Parkinson’s disease. Front. Pharmacol. 2019, 10, 1414. [Google Scholar] [CrossRef] [Green Version]
- Oliveira, L.M.; Falquetto, B.; Moreira, T.S.; Takakura, A.C. Orexinergic neurons are involved in the chemosensory control of breathing during the dark phase in a Parkinson’s disease model. Exp. Neurol. 2018, 309, 107–118. [Google Scholar] [CrossRef] [PubMed]
- Yang, L.; Wang, H.; Liu, L.; Xie, A. The role of insulin/IGF-1/PI3K/Akt/GSK3β signaling in parkinson’s disease dementia. Front. Neurosci. 2018, 12, 73. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wilhelm, K.R.; Yanamandra, K.; Gruden, M.A.; Zamotin, V.; Malisauskas, M.; Casaite, V.; Darinskas, A.; Forsgren, L.; Morozova-Roche, L.A. Immune reactivity towards insulin, its amyloid and protein S100B in blood sera of Parkinson’s disease patients. Eur. J. Neurol. 2007, 14, 327–334. [Google Scholar] [CrossRef]
- Fiory, F.; Perruolo, G.; Cimmino, I.; Cabaro, S.; Pignalosa, F.C.; Miele, C.; Beguinot, F.; Formisano, P.; Oriente, F. The Relevance of Insulin Action in the Dopaminergic System. Front. Neurosci. 2019, 13, 868. [Google Scholar] [CrossRef] [Green Version]
- Morris, J.K.; Seim, N.B.; Bomhoff, G.L.; Geiger, P.C.; Stanford, J.A. Effects of unilateral nigrostriatal dopamine depletion on peripheral glucose tolerance and insulin signaling in middle aged rats. Neurosci. Lett. 2011, 504, 219–222. [Google Scholar] [CrossRef] [Green Version]
- Morris, J.K.; Bomhoff, G.L.; Stanford, J.A.; Geiger, P.C. Neurodegeneration in an animal model of Parkinson’s disease is exacerbated by a high-fat diet. Am. J. Physiol. Integr. Comp. Physiol. 2010, 299, R1082–R1090. [Google Scholar] [CrossRef] [Green Version]
- Wilcox, B.J.; Matsumoto, A.M.; Dorsa, D.M.; Baskin, D.G. Reduction of insulin binding in the arcuate nucleus of the rat hypothalamus after 6-hydroxydopamine treatment. Brain Res. 1989, 500, 149–155. [Google Scholar] [CrossRef] [PubMed]
- Rabie, M.A.; Abd El Fattah, M.A.; Nassar, N.N.; El-Abhar, H.S.; Abdallah, D.M. Angiotensin 1-7 ameliorates 6-hydroxydopamine lesions in hemiparkinsonian rats through activation of MAS receptor/PI3K/Akt/BDNF pathway and inhibition of angiotensin II type-1 receptor/NF-κB axis. Biochem. Pharmacol. 2018, 151, 126–134. [Google Scholar] [CrossRef]
- Gao, S.; Duan, C.; Gao, G.; Wang, X.; Yang, H. Alpha-synuclein overexpression negatively regulates insulin receptor substrate 1 by activating mTORC1/S6K1 signaling. Int. J. Biochem. Cell Biol. 2015, 64, 25–33. [Google Scholar] [CrossRef] [PubMed]
- Fetterly, T.L.; Oginsky, M.F.; Nieto, A.M.; Alonso-Caraballo, Y.; Santana-Rodriguez, Z.; Ferrario, C.R. Insulin bidirectionally alters nac glutamatergic transmission: Interactions between insulin receptor activation, endogenous opioids, and glutamate release. J. Neurosci. 2021, 41, 2360–2372. [Google Scholar] [CrossRef] [PubMed]
- Ferrario, C.R.; Reagan, L.P. Insulin-mediated synaptic plasticity in the CNS: Anatomical, functional and temporal contexts. Neuropharmacology 2018, 136, 182–191. [Google Scholar] [CrossRef] [PubMed]
- Iravanpour, F.; Dargahi, L.; Rezaei, M.; Haghani, M.; Heidari, R.; Valian, N.; Ahmadiani, A. Intranasal insulin improves mitochondrial function and attenuates motor deficits in a rat 6-OHDA model of Parkinson’s disease. CNS Neurosci. Ther. 2021, 27, 308–319. [Google Scholar] [CrossRef]
- Pang, Y.; Lin, S.; Wright, C.; Shen, J.; Carter, K.; Bhatt, A.; Fan, L.W. Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats. Neuroscience 2016, 318, 157–165. [Google Scholar] [CrossRef] [Green Version]
- Chater, T.E.; Goda, Y. The role of AMPA receptors in postsynaptic mechanisms of synaptic plasticity. Front. Cell. Neurosci. 2014, 8, 401. [Google Scholar] [CrossRef]
- Zhang, H.; Bramham, C.R. Bidirectional Dysregulation of AMPA Receptor-Mediated Synaptic Transmission and Plasticity in Brain Disorders. Front. Synaptic Neurosci. 2020, 12, 26. [Google Scholar] [CrossRef] [PubMed]
- Duty, S.; Jenner, P. Animal models of Parkinson’s disease: A source of novel treatments and clues to the cause of the disease. Br. J. Pharmacol. 2011, 164, 1357–1391. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- He, Y.; Lee, T.; Leong, S.K. Effect of 6-OHDA injection on the AMPA glutamate receptor subunits in the substantia nigra of Sprague-Dawley rats. Neurosci. Lett. 1998, 241, 1–4. [Google Scholar] [CrossRef] [PubMed]
- Johnson, K.A.; Conn, P.J.; Niswender, C.M. Glutamate receptors as therapeutic targets for Parkinson’s disease. CNS Neurol Disord Drug Targets 2009, 8, 475–491. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Knezovic, A.; Piknjac, M.; Osmanovic Barilar, J.; Babic Perhoc, A.; Virag, D.; Homolak, J.; Salkovic-Petrisic, M. Association of Cognitive Deficit with Glutamate and Insulin Signaling in a Rat Model of Parkinson’s Disease. Biomedicines 2023, 11, 683. https://doi.org/10.3390/biomedicines11030683
Knezovic A, Piknjac M, Osmanovic Barilar J, Babic Perhoc A, Virag D, Homolak J, Salkovic-Petrisic M. Association of Cognitive Deficit with Glutamate and Insulin Signaling in a Rat Model of Parkinson’s Disease. Biomedicines. 2023; 11(3):683. https://doi.org/10.3390/biomedicines11030683
Chicago/Turabian StyleKnezovic, Ana, Marija Piknjac, Jelena Osmanovic Barilar, Ana Babic Perhoc, Davor Virag, Jan Homolak, and Melita Salkovic-Petrisic. 2023. "Association of Cognitive Deficit with Glutamate and Insulin Signaling in a Rat Model of Parkinson’s Disease" Biomedicines 11, no. 3: 683. https://doi.org/10.3390/biomedicines11030683